Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management

Advances in Anatomic Pathology

Volumn 20, Issue 2, 2013, Pages 117-124

  Shah, Rajal B ^a  

^a MIRACA LIFE SCIENCES   (United States)

Author keywords

ERG antibody; prostate cancer; TMPRSS2:ERG gene fusions

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; CELL MARKER; CYTOKERATIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P63; TRANSCRIPTION FACTOR ERG;

CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CLINICAL PRACTICE; DISEASE ASSOCIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; GENE FUSION; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICE; ONCOGENE PROTEINS, FUSION; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RABBITS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873898811     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3182862ac5     Document Type: Review

References (56)

1. Shah RB, Chinnaiyan AM. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)- erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications. Adv Anat Pathol. 2009; 16: 145-153.
2. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310: 644-648.
3. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol. 2007; 20: 538-544.
4. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009; 15: 4706-4711.
5. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006; 66: 8337-8341.
6. Han B, Mehra R, Dhanasekaran SM, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 2008; 68: 7629-7637.
7. Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2: ETV5 and SLC45A3: ETV5 gene fusions in prostate cancer. Cancer Res. 2008; 68: 73-80.
8. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERGpositive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010; 13: 228-237.
9. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009; 22: 1083-1093.
10. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res. 2008; 14: 3380-3385.
11. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007; 31: 882-888.
12. Mehra R, Han B, Tomlins SA, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 2007; 67: 7991-7995.
13. Mehra R, Tomlins SA, Yu J, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008; 68: 3584-3590.
14. Rosen P, Sesterhenn IA, Brassell SA, et al. Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol. 2012; 9: 131-137.
15. Han B, Suleman K, Wang L, et al. ETS gene aberrations in atypical cribriform lesions of the prostate: implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol. 2010; 34: 478-485.
16. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010; 12: 590-598.
17. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005; 24: 3847-3852.
18. Chaux A, Albadine R, Toubaji A, et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol. 2011; 35: 1014-1020.
19. Falzarano SM, Zhou M, Carver P, et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch. 2011; 459: 441-447.
20. van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol. 2011; 24: 1128-1138.
21. Braun M, Goltz D, Shaikhibrahim Z, et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer - a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis. 2012; 15: 165-169.
22. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol. 2005; 22: 88-104.
23. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology. 2005; 47: 1-16.
24. Przybycin CG, Kunju LP, Wu AJ, et al. Partial atrophy in prostate needle biopsies: a detailed analysis of its morphology, immunophenotype, and cellular kinetics. Am J Surg Pathol. 2008; 32: 58-64.
25. Shah RB, Kunju LP, Shen R, et al. Usefulness of basal cell cocktail (34betaE12 +p63) in the diagnosis of atypical prostate glandular proliferations. Am J Clin Pathol. 2004; 122: 517-523.
26. Shah RB, Zhou M, LeBlanc M, et al. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol. 2002; 26: 1161-1168.
27. Oliai BR, Kahane H, Epstein JI. Can basal cells be seen in adenocarcinoma of the prostate?: An immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody. Am J Surg Pathol. 2002; 26: 1151-1160.
28. Osunkoya AO, Hansel DE, Sun X, et al. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol. 2008; 32: 461-467.
29. Kunju LP, Chinnaiyan AM, Shah RB. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer. Histopathology. 2005; 47: 587-596.
30. Kunju LP, Rubin MA, Chinnaiyan AM, et al. Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. Am J Clin Pathol. 2003; 120: 737-745.
31. Yaskiv O, Zhang X, Simmerman K, et al. The utility of ERG/ P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol. 2011; 35: 1062-1068.
32. Tomlins SA, Palanisamy N, Siddiqui J, et al. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med. 2012; 136: 935-946.
33. Shah RB, Tadros Y, Brummell B, et al. The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and alpha-methylacyl-CoA- racemase markers. Hum Pathol. 2012, Nov. 14. [Epub ahead of print].
34. Gao X, Li LY, Zhou FJ, et al. ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis. Clin Cancer Res. 2012; 18: 4163-4172.
35. He H, Osunkoya AO, Carver P, et al. Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN. BJU Int. 2012. Oct 9. [Epub ahead of print].
36. He H, Magi-Galluzzi C, Li J, et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer". Am J Surg Pathol. 2011; 35: 608-614.
37. Shah RB, Magi-Galluzzi C, Han B, et al. Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies. Am J Surg Pathol. 2010; 34: 470-477.
38. Shah RB, Zhou M. Atypical cribriform lesions of the prostate: clinical significance, differential diagnosis and current concept of intraductal carcinoma of the prostate. Adv Anat Pathol. 2012; 19: 270-278.
39. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol. 2006; 175: 820-834.
40. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2008; 27: 253-263.
41. Wang WL, Patel NR, Caragea M, et al. Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma. Mod Pathol. 2012; 25: 1378-1383.
42. Miettinen M, Wang ZF, Paetau A, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol. 2011; 35: 432-441.
43. Minner S, Luebke AM, Kluth M, et al. High level of Etsrelated gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers. Histopathology. 2012; 61: 445-453.
44. Guo CC, Dancer JY, Wang Y, et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol. 2011; 42: 11-17.
45. Han B, Mehra R, Suleman K, et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol. 2009; 22: 1176-1185.
46. Nam RK, Sugar L, Wang Z, et al. Expression of TMPRSS2: ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther. 2007; 6: 40-45.
47. Demichelis F, Fall K, Perner S, et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007; 26: 4596-4599.
48. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2- ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009; 69: 1400-1406.
49. Hermans KG, Boormans JL, Gasi D, et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res. 2009; 15: 6398-6403.
50. Pettersson A, Graff RE, Bauer SR, et al. The TMPRSS2: ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1497-1509.
51. Minner S, Enodien M, Sirma H, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res. 2011; 17: 5878-5888.
52. Hoogland AM, Jenster G, van Weerden WM, et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol. 2012; 25: 471-479.
53. Reid AH, Attard G, Ambroisine L, et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer. 2010; 102: 678-684.
54. Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol. 2008; 21: 1451-1460.
55. Brenner JC, Ateeq B, Li Y, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011; 19: 664-678.
56. Roach M III, DeSilvio M, Valicenti R, et al. Whole-pelvis, "mini-pelvis, " or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys. 2006; 66: 647-653.